CGTX Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Cognition Therapeutics's net margin of -49.65%. Cognition Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Cognition Therapeutics has a consensus price target of $5.40, signalling upside risk potential of 1536.36%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 49.07%. Given that Cognition Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Cognition Therapeutics is more attractive than NovaBay Pharmaceuticals.

Cognition Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Cognition Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Cognition Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Cognition Therapeutics's net income of -$7.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Cognition Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics is -- versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

PDS Biotechnology has a net margin of -- compared to Cognition Therapeutics's net margin of --. Cognition Therapeutics's return on equity of -- beat PDS Biotechnology's return on equity of --.

Cognition Therapeutics has a consensus price target of $5.40, signalling upside risk potential of 1536.36%. On the other hand PDS Biotechnology has an analysts' consensus of $7.50 which suggests that it could grow by 514.75%. Given that Cognition Therapeutics has higher upside potential than PDS Biotechnology, analysts believe Cognition Therapeutics is more attractive than PDS Biotechnology.

Cognition Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PDS Biotechnology has a beta of 1.397, suggesting its more volatile than the S&P 500 by 39.741%.

Cognition Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PDS Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics pays -- of its earnings as a dividend. PDS Biotechnology pays out -- of its earnings as a dividend.

Cognition Therapeutics quarterly revenues are --, which are smaller than PDS Biotechnology quarterly revenues of --. Cognition Therapeutics's net income of -$7.8M is higher than PDS Biotechnology's net income of -$10.7M. Notably, Cognition Therapeutics's price-to-earnings ratio is -- while PDS Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics is -- versus -- for PDS Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.

Rafarma Pharmaceuticals has a net margin of -- compared to Cognition Therapeutics's net margin of --. Cognition Therapeutics's return on equity of -- beat Rafarma Pharmaceuticals's return on equity of --.

Cognition Therapeutics has a consensus price target of $5.40, signalling upside risk potential of 1536.36%. On the other hand Rafarma Pharmaceuticals has an analysts' consensus of -- which suggests that it could fall by --. Given that Cognition Therapeutics has higher upside potential than Rafarma Pharmaceuticals, analysts believe Cognition Therapeutics is more attractive than Rafarma Pharmaceuticals.

Cognition Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rafarma Pharmaceuticals has a beta of 1.185, suggesting its more volatile than the S&P 500 by 18.453%.

Cognition Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rafarma Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics pays -- of its earnings as a dividend. Rafarma Pharmaceuticals pays out -- of its earnings as a dividend.

Cognition Therapeutics quarterly revenues are --, which are smaller than Rafarma Pharmaceuticals quarterly revenues of --. Cognition Therapeutics's net income of -$7.8M is higher than Rafarma Pharmaceuticals's net income of --. Notably, Cognition Therapeutics's price-to-earnings ratio is -- while Rafarma Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics is -- versus -- for Rafarma Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Tonix Pharmaceuticals Holding has a net margin of -- compared to Cognition Therapeutics's net margin of -856.24%. Cognition Therapeutics's return on equity of -- beat Tonix Pharmaceuticals Holding's return on equity of -138.47%.

Cognition Therapeutics has a consensus price target of $5.40, signalling upside risk potential of 1536.36%. On the other hand Tonix Pharmaceuticals Holding has an analysts' consensus of $60.00 which suggests that it could grow by 216.79%. Given that Cognition Therapeutics has higher upside potential than Tonix Pharmaceuticals Holding, analysts believe Cognition Therapeutics is more attractive than Tonix Pharmaceuticals Holding.

Cognition Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding has a beta of 1.627, suggesting its more volatile than the S&P 500 by 62.658%.

Cognition Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cognition Therapeutics pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding pays out -- of its earnings as a dividend.

Cognition Therapeutics quarterly revenues are --, which are smaller than Tonix Pharmaceuticals Holding quarterly revenues of $2.6M. Cognition Therapeutics's net income of -$7.8M is higher than Tonix Pharmaceuticals Holding's net income of -$22.1M. Notably, Cognition Therapeutics's price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cognition Therapeutics is -- versus 2.38x for Tonix Pharmaceuticals Holding. Usually stocks with elevated PS ratios are considered overvalued.